What is Organogenesis?
Organogenesis is a leading regenerative medicine company dedicated to advancing healing through the development, manufacturing, and commercialization of innovative products. Its focus spans critical markets, including advanced wound care and surgical and sports medicine. The company's product portfolio aims to address unmet clinical needs, offering solutions that empower healthcare professionals and improve patient outcomes in complex healing scenarios. The company's commitment to scientific rigor and market penetration positions it as a key entity in the rapidly evolving landscape of regenerative therapies.
How much funding has Organogenesis raised?
Organogenesis has raised a total of $182.4M across 5 funding rounds:
Grant
$7.4M
Private Equity
$30M
Debt
$25M
Private Equity
$20M
Unspecified
$100M
Grant (2012): $7.4M with participation from Massachusetts Life Sciences Center
Private Equity (2016): $30M, investors not publicly disclosed
Debt (2017): $25M supported by Silicon Valley Bank
Private Equity (2017): $20M featuring EASTWARD CAPITAL PARTNERS
Unspecified (2019): $100M backed by MidCap Financial and Silicon Valley Bank
Key Investors in Organogenesis
Silicon Valley Bank
Silicon Valley Bank is a financial institution known for its specialized services to the technology and healthcare sectors, providing commercial and private banking solutions that support innovation and growth.
MidCap Financial
MidCap Financial specializes in providing tailored and efficient financing solutions, particularly for companies seeking to scale their operations and capitalize on market opportunities.
Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center is a state-backed entity focused on fostering innovation and economic growth within the life sciences sector through strategic investments and support for research and commercialization.
What's next for Organogenesis?
The recent major strategic investment of $100M signals Organogenesis's readiness for its next phase of expansion and product development. This capital infusion is likely to accelerate the company's go-to-market strategies, enhance its manufacturing capabilities, and potentially fuel further research into novel regenerative medicine applications. Given the enterprise-level context of its total funding, Organogenesis appears poised to solidify its leadership in the advanced wound care and surgical markets, potentially exploring new therapeutic areas or expanding its global reach. The strategic nature of the recent financing suggests a focus on long-term value creation and market dominance.
See full Organogenesis company page
